SG11201906644YA - Pparϒ agonist for the treatment of huntington's disease - Google Patents
Pparϒ agonist for the treatment of huntington's diseaseInfo
- Publication number
- SG11201906644YA SG11201906644YA SG11201906644YA SG11201906644YA SG11201906644YA SG 11201906644Y A SG11201906644Y A SG 11201906644YA SG 11201906644Y A SG11201906644Y A SG 11201906644YA SG 11201906644Y A SG11201906644Y A SG 11201906644YA SG 11201906644Y A SG11201906644Y A SG 11201906644YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- suite
- huntington
- pct
- disease
- Prior art date
Links
- 208000023105 Huntington disease Diseases 0.000 title abstract 3
- 239000000556 agonist Substances 0.000 title abstract 3
- 241001481833 Coryphaena hippurus Species 0.000 abstract 3
- 240000005020 Acaciella glauca Species 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 235000003499 redwood Nutrition 0.000 abstract 2
- NMRWDFUZLLQSBN-UHFFFAOYSA-N 2,4-dichloro-n-(3,5-dichloro-4-quinolin-3-yloxyphenyl)benzenesulfonamide Chemical compound ClC1=CC(Cl)=CC=C1S(=O)(=O)NC(C=C1Cl)=CC(Cl)=C1OC1=CN=C(C=CC=C2)C2=C1 NMRWDFUZLLQSBN-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 229940068196 placebo Drugs 0.000 abstract 1
- 239000000902 placebo Substances 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 239000002023 wood Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762447741P | 2017-01-18 | 2017-01-18 | |
| PCT/US2018/014240 WO2018136635A1 (en) | 2017-01-18 | 2018-01-18 | Pparϒ agonist for the treatment of huntington's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201906644YA true SG11201906644YA (en) | 2019-08-27 |
Family
ID=62908392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906644YA SG11201906644YA (en) | 2017-01-18 | 2018-01-18 | Pparϒ agonist for the treatment of huntington's disease |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190350918A1 (enExample) |
| EP (1) | EP3570841A4 (enExample) |
| JP (1) | JP2020505448A (enExample) |
| KR (1) | KR20190122664A (enExample) |
| CN (1) | CN110461330A (enExample) |
| AU (1) | AU2018210165A1 (enExample) |
| BR (1) | BR112019014529A2 (enExample) |
| CA (1) | CA3050104A1 (enExample) |
| EA (1) | EA201991716A1 (enExample) |
| IL (1) | IL268008A (enExample) |
| MX (1) | MX2019008535A (enExample) |
| SG (1) | SG11201906644YA (enExample) |
| WO (1) | WO2018136635A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016229982B2 (en) | 2015-03-09 | 2020-06-18 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
| JP2020515639A (ja) | 2017-04-03 | 2020-05-28 | コヒラス・バイオサイエンシズ・インコーポレイテッド | 進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8895541B2 (en) * | 2002-09-04 | 2014-11-25 | James A. Carnazza | Methods for inhibiting the development of huntington's disease |
| US20040224995A1 (en) * | 2003-05-09 | 2004-11-11 | University Of North Texas Health Science Center At Fort Worth | Neuroprotective effects of PPARy agonists against cellular oxidative insults |
| US7223761B2 (en) * | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| DE10351744A1 (de) * | 2003-10-31 | 2005-06-16 | Schering Ag | Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel |
| JP2008515978A (ja) * | 2004-10-13 | 2008-05-15 | ユニバーシティ オブ コネチカット | カンナビネルジック脂質リガンド |
| WO2009097996A1 (de) * | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Verwendung von substituierten phenylimidazolidinen zur herstellung von arzneimitteln zur behandlung des metabolischen syndroms |
| WO2010040055A2 (en) * | 2008-10-03 | 2010-04-08 | Intekrin Therapeutics, Inc. | Oral pharmaceutical formulations for antidiabetic compounds |
| EP2448412B1 (en) * | 2009-07-01 | 2019-05-01 | JDS Therapeutics, LLC | Chromium complexes as enhancers of brain glucose transporters |
| AU2014364447A1 (en) * | 2013-12-20 | 2016-08-04 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod to delay Huntington's disease progression |
-
2018
- 2018-01-18 AU AU2018210165A patent/AU2018210165A1/en not_active Abandoned
- 2018-01-18 CN CN201880007571.4A patent/CN110461330A/zh active Pending
- 2018-01-18 BR BR112019014529-0A patent/BR112019014529A2/pt not_active Application Discontinuation
- 2018-01-18 EA EA201991716A patent/EA201991716A1/ru unknown
- 2018-01-18 EP EP18741523.7A patent/EP3570841A4/en not_active Withdrawn
- 2018-01-18 CA CA3050104A patent/CA3050104A1/en not_active Abandoned
- 2018-01-18 JP JP2019559015A patent/JP2020505448A/ja active Pending
- 2018-01-18 KR KR1020197023202A patent/KR20190122664A/ko not_active Ceased
- 2018-01-18 MX MX2019008535A patent/MX2019008535A/es unknown
- 2018-01-18 WO PCT/US2018/014240 patent/WO2018136635A1/en not_active Ceased
- 2018-01-18 US US16/476,979 patent/US20190350918A1/en not_active Abandoned
- 2018-01-18 SG SG11201906644YA patent/SG11201906644YA/en unknown
-
2019
- 2019-07-11 IL IL268008A patent/IL268008A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018136635A1 (en) | 2018-07-26 |
| AU2018210165A1 (en) | 2019-08-01 |
| KR20190122664A (ko) | 2019-10-30 |
| JP2020505448A (ja) | 2020-02-20 |
| EP3570841A1 (en) | 2019-11-27 |
| CA3050104A1 (en) | 2018-07-26 |
| IL268008A (en) | 2019-09-26 |
| US20190350918A1 (en) | 2019-11-21 |
| BR112019014529A2 (pt) | 2020-02-27 |
| EA201991716A1 (ru) | 2020-02-04 |
| CN110461330A (zh) | 2019-11-15 |
| MX2019008535A (es) | 2019-12-02 |
| EP3570841A4 (en) | 2020-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201906373VA (en) | Chemical compounds as inhibitors of interleukin-1 activity | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201901747VA (en) | Inhibitors of cellular metabolic processes | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201809559UA (en) | Substituted pyridines as inhibitors of dnmt1 | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201808799SA (en) | Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201811237WA (en) | Combination therapies | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201900486WA (en) | Treatment and prevention of sleep disorders | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201908114UA (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| SG11201901347UA (en) | Compositions and methods for cancer immunotherapy | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201902949PA (en) | Pharmaceutical compositions and methods of treating cardiovascular diseases | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201807596YA (en) | Gitr antibodies, methods, and uses | |
| SG11201901228QA (en) | Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide | |
| SG11201909837YA (en) | Methods for treating lung disorders |